Sign inJoin waitlistJoin the waitlist

Courtney DiNardo

Associate Medical Director · University of Texas M D Anderson Cancer Center

Credentials: · · · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
2009–2012
Internal Medicine
2006–2009
University of Michigan Medical School
2002–2006

Research

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Blood · 2022 · 2,814 citations
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine · 2020 · First of 30 authors · 2,437 citations

Tapan Kadia
322 papers
Hagop Kantarjian
311 papers
Naval Daver
303 papers
Guillermo Garcia-Manero
269 papers
GB
Gautam Borthakur
225 papers
Elias Jabbour
224 papers
Marina Konopleva
206 papers
Nicholas Short
189 papers · 9 as a fellow
Naveen Pemmaraju
172 papers
KS
Koji Sasaki
145 papers · 7 as a fellow
Sanam Loghavi
135 papers · 1 as a fellow
Ghayas Issa
128 papers · 1 as a fellow

Grants

T32 Research Training in Academic Medical Oncology
National Cancer Institute · T32
PI · $1.6M · University of Tx Md Anderson Can Ctr
1994–2031
Role of Targeting ATPases BRG1/BRM in Therapy of AML
National Cancer Institute · R01
PI · $1.1M · University of Tx Md Anderson Can Ctr
2025–2030
Biology and Novel Therapy of AML Expressing Somatic or Germline Mutant RUNX1
National Cancer Institute · R01
PI · $2.4M · University of Tx Md Anderson Can Ctr
2020–2025
Novel Combination Therapy for AML Expressing Mutant RUNX1
National Cancer Institute · R01
Contact PI · $2.1M · University of Tx Md Anderson Can Ctr
2021–2025

Clinical trials

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2029
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2029
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2025–2029
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2028